Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (261-270 of 390) with videos related to

Pageof 39
Sort By:
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|April 10, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885]Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|March 15, 2026
Characterising executive functioning in the chronic phase of autoimmune encephalitis: A study by the Australian autoimmune encephalitis consortiumKatherine Y Ko, Nabil Seery, Sarah Griffith, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Pageof 39

Showing results (261-270 of 390) with videos related to

Sort By:
Pageof 39
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|April 10, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885]Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Multiple Sclerosis and Related Disorders|March 15, 2026
Characterising executive functioning in the chronic phase of autoimmune encephalitis: A study by the Australian autoimmune encephalitis consortiumKatherine Y Ko, Nabil Seery, Sarah Griffith, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Pageof 39